Nebius Raises Revenue Target to $9B but Capex Soars to $25B, Amplifying Funding Risk

What happened

Nebius now targets $7 billion to $9 billion in annualized run-rate revenue by year-end 2026, up from $3 billion in June, but plans $20 billion to $25 billion in capital spending this year. That capex range implies a dramatic second-half acceleration from the $8.13 billion spent in the first half, requiring substantial additional financing beyond the $5.75 billion convertible and $775 million secured loan already raised. Recent insider selling, including coordinated sales by the CEO, CTO, and COO, adds a cautionary signal on top of the company's already high customer concentration and adverse internal-controls opinion. The stock still trades at around 77 times EV/EBITDA, leaving little room for execution missteps. Investors now await the November 12 earnings release for concrete evidence that capacity is energizing and that prepayments are keeping pace with capex.

Implication

The updated capex of $20-25 billion for 2026 significantly widens the funding gap versus operating cash flow, which relied heavily on customer prepayments in the first half. If deferred-revenue growth fails to match the accelerated buildout, Nebius will likely need another dilutive equity-linked raise, pressuring the stock. The upcoming November 12 report is a critical checkpoint for capacity energization and updated prepayment guidance. Until Nebius demonstrates that it can fund expansion without frequent capital raises, the bear case of $130 becomes more plausible than the bull case of $230. Consider adding only near the $145 attractive entry level or after two consecutive quarters of clean execution and no new financing surprises.

Thesis delta

The new disclosure of $20-25 billion capex for 2026, versus $8.13 billion in the first half, materially increases the company's external financing needs and dilution risk. The higher revenue target is encouraging but depends on near-flawless capacity delivery and customer prepayments. This tilts the risk-reward slightly more negative; the WAIT rating stands but with a higher bar for new buying.